Karisa Colleen Schreck - Publications

2012 Johns Hopkins University, Baltimore, MD 

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Schreck KC, Patel MP, Wemmer J, Grossman SA, Peters KB. RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events. Neuro-Oncology Practice. 7: 369-375. PMID 32765888 DOI: 10.1093/Nop/Npaa006  0.33
2020 Naidoo J, Schreck KC, Hu C, Douville CB, Santa-Maria CA, Connolly RM, Holdhoff M, Lipson EJ, Parkinson R, Riemer J, Barnes A, Venkatesan A, Bettegowda C, Grossman SA, Brahmer JR. Anti-PD-1 for patients with leptomeningeal metastasis from advanced solid tumors: Efficacy, safety, and biomarkers of response. Journal of Clinical Oncology. 38: e14506-e14506. DOI: 10.1200/Jco.2020.38.15_Suppl.E14506  0.339
2019 Schreck KC, Grossman SA, Pratilas CA. BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors. Cancers. 11. PMID 31466300 DOI: 10.3390/Cancers11091262  0.417
2019 Ananth YV, Schreck K. CGE19-063: Creating a Clinical-Molecular Database to Study Patients with BRAF V600E-Mutated Brain Tumors Journal of the National Comprehensive Cancer Network. 17: CGE19-063. DOI: 10.6004/Jnccn.2018.7137  0.417
2019 Schreck KC, Allen A, Wang J, Pratilas CA. Abstract B074: Sapanisertib in combination with trametinib in glioblastoma models enhances target inhibition and antitumor activity Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B074  0.397
2018 Schreck KC, Grossman SA. Role of Temozolomide in the Treatment of Cancers Involving the Central Nervous System. Oncology (Williston Park, N.Y.). 32: 555-60, 569. PMID 30474103  0.328
2018 Schreck KC, Guajardo A, Lin DDM, Eberhart CG, Grossman SA. Concurrent BRAF/MEK Inhibitors in V600-Mutant High-Grade Primary Brain Tumors. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 343-347. PMID 29632053 DOI: 10.6004/Jnccn.2017.7052  0.445
2015 Brandt WD, Schreck KC, Bar EE, Taylor I, Marchionni L, Raabe E, Eberhart CG, Rodriguez FJ. Notch signaling activation in pediatric low-grade astrocytoma. Journal of Neuropathology and Experimental Neurology. 74: 121-31. PMID 25575134 DOI: 10.1097/Nen.0000000000000155  0.516
2015 Brandt WD, Schreck KC, Bar EE, Taylor I, Marchionni L, Raabe E, Eberhart CG, Rodriguez FJ. Lg-04Notch Signaling Activation In Pediatric Low-Grade Astrocytoma. Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov061.73  0.52
2013 Heaphy CM, Schreck KC, Raabe E, Mao XG, An P, Chu Q, Poh W, Jiao Y, Rodriguez FJ, Odia Y, Meeker AK, Eberhart CG. A glioblastoma neurosphere line with alternative lengthening of telomeres. Acta Neuropathologica. 126: 607-8. PMID 24022427 DOI: 10.1007/S00401-013-1174-X  0.371
2012 Asnaghi L, Ebrahimi KB, Schreck KC, Bar EE, Coonfield ML, Bell WR, Handa J, Merbs SL, Harbour JW, Eberhart CG. Notch signaling promotes growth and invasion in uveal melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 654-65. PMID 22228632 DOI: 10.1158/1078-0432.Ccr-11-1406  0.459
2011 Pierfelice TJ, Schreck KC, Dang L, Asnaghi L, Gaiano N, Eberhart CG. Notch3 activation promotes invasive glioma formation in a tissue site-specific manner. Cancer Research. 71: 1115-25. PMID 21245095 DOI: 10.1158/0008-5472.Can-10-0690  0.648
2011 Asnaghi L, Coonfield ML, Schreck KC, Bar EE, Handa J, Merbs S, Ebrahimi KB, Harbour JW, Eberhart CG. Abstract 1415: The Notch ligand Jag 2 promotes growth and invasion in uveal melanoma cells Cancer Research. 71: 1415-1415. DOI: 10.1158/1538-7445.Am2011-1415  0.4
2010 Schreck KC, Taylor P, Marchionni L, Gopalakrishnan V, Bar EE, Gaiano N, Eberhart CG. The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 6060-70. PMID 21169257 DOI: 10.1158/1078-0432.Ccr-10-1624  0.733
2010 Silver DL, Watkins-Chow DE, Schreck KC, Pierfelice TJ, Larson DM, Burnetti AJ, Liaw HJ, Myung K, Walsh CA, Gaiano N, Pavan WJ. The exon junction complex component Magoh controls brain size by regulating neural stem cell division. Nature Neuroscience. 13: 551-8. PMID 20364144 DOI: 10.1038/Nn.2527  0.667
2010 Asnaghi L, Coonfield ML, Schreck KC, Bar EE, Handa J, Merbs S, Ebrahimi K, Harbour JW, Eberhart CG. Abstract 4141: Notch signaling: A new potential target in the treatment of uveal melanoma Cancer Research. 70: 4141-4141. DOI: 10.1158/1538-7445.Am10-4141  0.423
2010 Schreck KC, Taylor P, Bar EE, Gopalakrishnan V, Gaiano N, Eberhart CG. Abstract 14: Targeting Notch in malignant brain tumors: Crosstalk with Hedgehog as a potential mechanism of treatment resistance Cancer Research. 70: 14-14. DOI: 10.1158/1538-7445.Am10-14  0.748
2009 Schreck KC, Gaiano N. PML: a tumor suppressor essential for neocortical development. Nature Neuroscience. 12: 108-10. PMID 19172164 DOI: 10.1038/Nn0209-108  0.738
2008 Pierfelice TJ, Schreck KC, Eberhart CG, Gaiano N. Notch, neural stem cells, and brain tumors. Cold Spring Harbor Symposia On Quantitative Biology. 73: 367-75. PMID 19022772 DOI: 10.1101/Sqb.2008.73.013  0.695
2007 Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, Piccirillo S, Vescovi AL, DiMeco F, Olivi A, Eberhart CG. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells (Dayton, Ohio). 25: 2524-33. PMID 17628016 DOI: 10.1634/Stemcells.2007-0166  0.572
Show low-probability matches.